BUDGETARY IMPACT OF INFLIXIMAB BIOSIMILAR IN THE TREATMENT OF PSORIASIS AND ULCERATIVE COLITIS IN THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM

被引：0
|
作者：
Alexandre, R. F. [1 ]
Salgado De Santana, C. F. [2 ]
Senna, T. [1 ]
机构：
[1] Pfizer, Sao Paulo, Brazil
[2] Pfizer, Santos, Brazil
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PBI17
引用
收藏
页码：S49 / S50
页数：2
相关论文
共 50 条
  • [1] BUDGET IMPACT ANALYSIS OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS IN THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM
    Holanda, P.
    Salgado De Santana, C.
    Senna, T.
    Carmo, L.
    Alexandre, R. F.
    VALUE IN HEALTH, 2021, 24 : S96 - S97
  • [2] COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS IN THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM
    Holanda, P.
    Salgado De Santana, C.
    Senna, T.
    Carmo, L.
    Alexandre, R. F.
    VALUE IN HEALTH, 2021, 24 : S96 - S96
  • [3] Budgetary impact of lipegfilgrastim to the Brazilian public healthcare system.
    Szende, Agota
    Allaire, Jason
    Urwongse, Jennifer
    Petti, Marco
    Mendez, Omar Tomey
    Mueller, Udo W.
    Vicente, Andre
    Stefani, Stephen D.
    Tang, Boxiong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] COST MINIMIZATION ANALYSIS OF BIOSIMILAR INFLIXIMAB IN BRAZILIAN SUPLEMENTARY HEALTHCARE SYSTEM
    Alexandre, R. F.
    Salgado De Santana, C. F.
    Senna, T.
    VALUE IN HEALTH, 2019, 22 : S49 - S49
  • [5] Marketing of the first biosimilar infliximab in France: what budgetary impact in the public hospitals of Paris?
    Bocquet, F.
    Fusier, I.
    Cordonnier, A. L.
    Lechat, P.
    Paubel, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 : 80 - 80
  • [6] First observations of the use of biosimilar infliximab for treatment of ulcerative colitis in paediatric population.
    Jarzebicka, D.
    Plocek, A.
    Sieczkowska, J.
    Toporowska-Kowalska, E.
    Kierkus, J.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S307 - S308
  • [7] A Cost-Utility Analysis of Infliximab Compared with Surgery for the Treatment of Ulcerative Colitis; A Public Payer Perspective
    Jones, Jennifer
    Worobetz, Lawrence
    Bedi, Anil
    Manns, Braden
    GASTROENTEROLOGY, 2009, 136 (05) : A172 - A172
  • [8] COST MINIMIZATION ANALYSIS IN THE SWITCH OF INFLIXIMAB FOR ITS BIOSIMILAR IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
    Alexandre, R. F.
    Squiassi, H. B.
    Santana, C. F.
    VALUE IN HEALTH, 2017, 20 (05) : A147 - A147
  • [9] Inpatient Infliximab Biosimilar Cost-Savings: Cost Analysis of Inpatient Treatment with Originator Infliximab (Remicade™) versus Biosimilar Infliximab (Renflexis™) for Acute Severe Ulcerative Colitis
    Cappuccio, Joseph M.
    Mehta, Neev
    Pellish, Randall
    DIGESTIVE DISEASES, 2024, 42 (05)
  • [10] The budgetary impact of 2 g mesalazine for the treatment of mild to moderate ulcerative colitis
    Lovelace, I.
    Tate, E.
    Knapp, S.
    Masure, J.
    Shields, G.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S200 - S201
12345